GAMA
WX

Graticule Asia Macro Advisors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-187,500
Closed -$7.92M – 134
2015
Q2 		$7.92M Buy
+187,500
New +$7.91M 0.38% 45

Other funds holding WX

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Graticule Asia Macro Advisors's WX Position: Q3 2015 in Review

Graticule Asia Macro Advisors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q3 2015, closing a stake of 187,500 shares — an estimated $7.92M sold.

Graticule Asia Macro Advisors first reported a position in WX in Q2 2015 and held it in 1 quarter. The position peaked at $7.92M in Q2 2015. 151 funds tracked by Wall St. Rank hold WX as of Q3 2015.

  • Graticule Asia Macro Advisors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q3 2015 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 187,500 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q3 2015, an estimated $7.92M.
  • Graticule Asia Macro Advisors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2015 and held it in 1 quarter.
  • Graticule Asia Macro Advisors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $7.92M in Q2 2015.
  • 151 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q3 2015.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.